JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

JNJ

237.78

+1.48%↑

UNH

268.4

-2.59%↓

TMO

542.28

-3.73%↓

ABT

109.09

+0.87%↑

ISRG

476.03

-0.43%↓

Начало・Списък с акции・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Затворен

1.09 -6.84

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.09

Максимум

1.19

Ключови измерители
By Trading Economics
Приходи	17M -26M
Служители	171
EBITDA	19M -23M

Препоръки
By TipRanks
Препоръки	Продай
12-месечна прогноза	+238.98% upside

Дивиденти
By Dow Jones
Следващи печалби	26.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-29M 73M
Предишно отваряне	7.93
Предишно затваряне	1.09

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

1.43 / 1.6 Подкрепа & съпротива

Pliant Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.02.2026 г., 23:57 ч. UTC

Печалби

Naver Has Record Year Despite Weaker Final Quarter

5.02.2026 г., 23:45 ч. UTC

Горещи акции

Stocks to Watch: Amazon, Coty, Gen Digital, Roblox

5.02.2026 г., 22:26 ч. UTC

Печалби

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9% -- Update

5.02.2026 г., 22:00 ч. UTC

Печалби

REA Group Lifts Dividend, Announces Buyback as 1st Half Profit Rises 9%

5.02.2026 г., 23:47 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

5.02.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Fall After U.S. Tech Stock Drops -- Market Talk

5.02.2026 г., 23:43 ч. UTC

Пазарно говорене

Gold Falls on Spillover Impact From Cryptocurrencies' Selloff -- Market Talk

5.02.2026 г., 23:37 ч. UTC

Пазарно говорене

Glencore Shares Look Cheap After Failed Takeover Talks -- Market Talk

5.02.2026 г., 23:20 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 5th Update

5.02.2026 г., 23:11 ч. UTC

Пазарно говорене

Amazon CEO Confident in Return on $200B Investment -- Market Talk

5.02.2026 г., 23:09 ч. UTC

Печалби

Naver 2025 Net KRW1.820T Vs. Net KRW1.932T >035420.SE

5.02.2026 г., 23:08 ч. UTC

Печалби

Naver 2025 Oper Pft KRW2.208T Vs. Pft KRW1.979T >035420.SE

5.02.2026 г., 23:07 ч. UTC

Печалби

Naver 2025 Rev KRW12.035T Vs. KRW10.738T >035420.SE

5.02.2026 г., 23:03 ч. UTC

Пазарно говорене

Печалби

REA's Update Looks Negative Despite A$200M Buyback -- Market Talk

5.02.2026 г., 23:03 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Bitcoin Booster's $12 Billion Loss Headlines Crypto's Worst Day Since 2022 Crash -- WSJ

5.02.2026 г., 23:00 ч. UTC

Печалби

Naver 4Q Net Profit Missed FactSet-Compiled Consensus

5.02.2026 г., 23:00 ч. UTC

Печалби

Naver 4Q Net KRW164.60B Vs. Net KRW514.00B >035420.SE

5.02.2026 г., 22:59 ч. UTC

Печалби

Naver 4Q Oper Pft KRW610.60B Vs. Pft KRW542.00B >035420.SE

5.02.2026 г., 22:59 ч. UTC

Печалби

Naver 4Q Rev KRW3.195T Vs. KRW2.886T >035420.SE

5.02.2026 г., 22:52 ч. UTC

Печалби

Alphabet Stock Is Taking a Hit After Strong Earnings. Don't Panic. -- Barrons.com

5.02.2026 г., 22:45 ч. UTC

Печалби

Amazon Stock Falls Sharply on Earnings. Spending Continues to Soar. -- Barrons.com

5.02.2026 г., 22:37 ч. UTC

Пазарно говорене

Woolworths's Profit Margin Likely Faces 2Q Squeeze -- Market Talk

5.02.2026 г., 22:11 ч. UTC

Печалби

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9% -- Update

5.02.2026 г., 22:03 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Amazon to Spend $200 Billion as It Accelerates AI Projects -- 4th Update

5.02.2026 г., 22:01 ч. UTC

Печалби

Reddit Stock Jumps on Earnings. CFO Cites Modest AI Spending. -- Barrons.com

5.02.2026 г., 21:59 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

What's Next For Rio Tinto, Glencore After Deal Talks Fail? -- Market Talk

5.02.2026 г., 21:51 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Saylor's Strategy Posts $12 Billion Quarterly Loss on Bitcoin Selloff -- WSJ

5.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Basic Materials Roundup: Market Talk

5.02.2026 г., 21:49 ч. UTC

Печалби

Why Google's Bad News Was Good News for Broadcom and Nvidia -- Barrons.com

5.02.2026 г., 21:45 ч. UTC

Печалби

REA Group Lifts Dividend, Announces Buyback as 1H Profit Rises 9%

Сравнение с други в отрасъла

Ценова промяна

Pliant Therapeutics Inc Прогноза

Ценова цел

By TipRanks

238.98% нагоре

12-месечна прогноза

Среден 4 USD 238.98%

Висок 4 USD

Нисък 4 USD

Според 3 анализатори от Wall Street, предложили 12-месечна ценова цел за Pliant Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Продай

3 ratings

Купи

Задържане

Продай

Според 3 анализатори, дали борсови рейтинги на Pliant Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.43 / 1.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

There is one bearish event.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.